Researchers test if time to next treatment can replace survival as a cancer trial endpoint
NCT ID NCT03963518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 631 advanced melanoma patients treated with immune checkpoint inhibitors. Researchers wanted to see if the time until a patient needs their next treatment or dies (TNT-D) is a good stand-in for overall survival. The goal was to find a quicker way to measure how well these drugs work in future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié, Comprehensive Cancer Center
Bordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- New combo therapy takes on advanced cancers
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?